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hile evidence is accumulating that phospho-
inositide signaling plays a crucial role in growth
factor and hormone receptor down-regulation,
this signaling pathway has also been proposed to regulate
endosomal membrane transport and multivesicular endo-
some biogenesis. Here, we have followed the fate of the
down-regulated EGF receptor (EGFR) and bulk transport
(ﬂuid phase) markers in the endosomal pathway in vivo
and in vitro. We ﬁnd that bulk transport from early to late
endosomes is not affected after inhibition of the phosphatidyl-
W
 
inositol-3-phosphate (PI3P) signaling pathway, but that the
EGFR then remains trapped in early endosomes. Similarly,
we ﬁnd that hepatocyte growth factor–regulated tyrosine
kinase substrate
 
 
 
(Hrs) is not directly involved in bulk solute
transport, but is required for EGFR sorting. These observations
thus show that transport and sorting can be uncoupled in the
endosomal pathway. They also show that PI3P signaling
does not regulate the core machinery of endosome biogenesis
and transport, but controls the sorting of down-regulated
receptor molecules in early endosomes via Hrs.
 
Introduction
 
Recent studies have highlighted the role of phosphatidyl-
inositol-3-phosphate
 
 (
 
PI3P) signaling in growth factor and
hormone receptor down-regulation (Simonsen et al., 2001).
Additionally, this signaling pathway has also been proposed
to regulate endosomal membrane transport and multivesicular
endosome biogenesis (Reaves et al., 1996; Fernandez-Borja
et al., 1999; Odorizzi et al., 2000; Futter et al., 2001). In
addition to PI 3-kinase, candidate effectors of this PI3P
signaling pathway include phosphoinositide-binding proteins,
including the PI3P 5-kinase Fab1p (Odorizzi et al., 1998),
hepatocyte growth factor–regulated tyrosine kinase substrate
(Hrs) in conjunction with other class E proteins (Bishop et
al., 2002; Raiborg et al., 2002), and members of the SNX
family (Haft et al., 1998; Sato et al., 2001). The precise
functions of these proteins in protein trafficking and mem-
brane transport are still unclear. More importantly, it is not
known to what extent this signaling pathway as such plays a
role in transport, protein sorting, or endosome biogenesis.
Here, we report that bulk transport from early to late endo-
somes, including biogenesis of endosomal intermediates and
their subsequent fusion with late endosomes, does not de-
pend on PI3P signaling, but that phosphoinositides tightly
control the sorting of down-regulated EGF receptor (EGFR)
in early endosomes via Hrs.
 
Results and discussion
 
Bulk transport from early to late endosomes was followed
with soluble markers that are incorporated nonselectively
within the endosomal content, e.g., fluorescent dextran or
HRP, whereas the EGFR was used as a reporter for the
trafficking of down-regulated receptors. Since solutes may
follow more than one endocytic pathways (Nichols and
Lippincott-Schwartz, 2001), the fate of endocytosed dextran
was first compared with that of down-regulated EGFR after
EGF treatment. After 10 min, both markers colocalized in
early endosomes (Fig. 1 A), containing the Rab5 effector
early endosomal antigen 1 (EEA1) (Simonsen et al., 1998).
After subsequent incubation for 45 min (not shown) or 90
min at 37
 
 
 
C, both EGFR and its ligand EGF reached vesicles
that contained the late endosomal-specific lipid, lysobisphos-
phatidic acid (LBPA) (Kobayashi et al., 1998) (not shown)
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Figure 1. Transport from early to late endosomes after PI3 kinase inhibition. (A) BHK cells expressing EGFR-GFP were preincubated with 
EGF for 1 h at 4 C and washed; this pretreatment was always used for EGF or EGFR endocytosis. Cells were incubated for 10 min at 37 C with 
rhodamine-dextran (pulse), labeled with antibodies against the indicated antigens, and analyzed by triple channel fluorescence microscopy. 
(B) BHK cells overexpressing EGFR-GFP were incubated with EGF-biotin and streptavidin-phycoerythrin for 1 h at 4 C and then for 10 min at 
37 C, followed by a 90-min chase in the presence of 0.5 mg/ml leupeptin and analyzed as in described for A; high magnification views of the 
indicated areas are shown below the micrographs. (C) A pulse of rhodamine dextran was endocytosed as described for A and then chased for 
45 min; cells were analyzed as described for A. (D) A pulse of rhodamine dextran was endocytosed as described for A into BHK cells with or 
without chase (as in C); 100 nM wortmannin (Wort) was present during both the pulse and the chase. Cells were analyzed as described for A. 
Bars: (A–C) 5  m; (D) 2.5  m.T
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or Lamp1 (Fig. 1 B), a very abundant protein of late endo-
somes and lysosomes (Aniento et al., 1993a; Griffiths et
al., 1988). Similarly, under the same conditions, dextran
reached vesicles that contained Lamp1 (not shown) or LBPA
(Fig. 1 C). Hence, both solutes and EGFR follow the same
pathway to early endosomes and then to late endocytic com-
partments.
When transport from early to late endosomes is inhib-
ited, HRP is regurgitated into the medium and fails to ac-
cumulate intracellularly (Clague et al., 1994; Gu et al.,
1997; Mayran et al., 2003). In contrast, when PI3 kinase
was inhibited with wortmannin, although HRP internaliza-
tion was decreased, accumulation was not affected (not
shown), suggesting that transport from early to late endo-
somes does not depend on PI3P signaling. Indeed, PI3 ki-
nase inhibition did not affect transport of dextran to late
endosomes containing LBPA (Fig. 1 D, and see quantifica-
tion in Fig. 3 C) or Lamp1 (see Fig. 3 A). As a control, we
confirmed that wortmannin did however lead to the release
of EEA1 from early endosomes (Fig. 1 D), and reduced the
PI3P content of early endosomal fractions (not shown). To
interfere more specifically with PI3P-dependent functions,
we used a double FYVE PI3P-binding domain (2xFYVE)
that binds PI3P with high specificity (not shown) and in-
hibits early endosome fusion in vitro (see Fig. 4 B), as
expected (Gillooly et al., 2000). When linked to GFP,
2xFYVE colocalized with dextran internalized for 10 min
and EEA1 on early endosomes (Fig. 2 A). In agreement
with the lack of effect of wortmannin, GFP-2xFYVE did
not affect dextran transport to late endosomes (Fig. 2 A,
and quantification in Fig. 3 C). Similarly, endocytosed
mouse IgGs, a fluid phase marker, were transported to lyso-
somes and degraded whether or not GFP-2xFYVE was ex-
pressed, whereas IgGs accumulated intracellularly when ly-
sosomal degradation was blocked with leupeptin (Fig. 2 B).
We thus concluded that PI3P signaling is not involved in
bulk endosomal membrane transport.
In marked contrast to our observations with solutes,
EGFR endocytosed for 45 min (Fig. 3 C) or even for 90 min
after EGF addition failed to reach late endocytic compart-
Figure 2. GFP-2xFYVE does not inhibit 
bulk transport to late endosomes in 
vivo. (A) As in Fig. 1 A, a pulse of 
rhodamine dextran was endocytosed 
with or without chase in cells expressing 
a double FYVE domain associated to 
GFP (GFP-2xFYVE). Cells were analyzed 
as described in the legend to Fig. 1 A. 
(B) Cells expressing or not expressing 
GFP-2xFYVE were incubated overnight 
with 40  g/ml mouse IgGs with or with-
out 50  g/ml leupeptin. Endocytosed 
IgGs were revealed using anti-mouse 
antibodies and cells were analyzed by 
double channel fluorescence microscopy. 
The total number of labeled vesicles 
(containing IgGs in red) was counted 
for each condition in control cells or 
cells expressing GFP-2xFYVE. Vesicles 
in  20 cells were counted for each 
condition in three different experiments. 
Numbers were similar whether GFP-
2xFYVE was present or not, and are 
expressed as a percentage of the total 
number of vesicles in leupeptin-treated 
cells, to facilitate direct comparison. 
Bar, 2.5  m.T
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ments containing LBPA (not shown) or Lamp1 (Fig. 3 A)
after inhibition of PI3 kinase with wortmannin. Then,
EGFR was trapped in early/recycling endosomes containing
the transferrin receptor (TfR) (Fig. 3 A and D, and quantifi-
cation in E). Solute transport was unaffected in the same
cells (Fig. 3 A). Similarly, endocytosed EGF was not trans-
ported to LBPA-containing late endosomes in cells express-
ing GFP-2xFYVE, but was trapped within early endosomes,
containing both EEA1 (not shown) and GFP-2xFYVE (Fig.
3 B, and quantification in C). In a previous study, the lyso-
somal degradation of EGFR preinternalized at 20
 
 
 
C was re-
ported to be insensitive to wortmannin (Futter et al., 2001),
perhaps because EGFR had been transported beyond the
early endosomal sorting checkpoint before drug addition
(Griffiths et al., 1988).
These differences between solute and receptor trafficking
prompted us to investigate the role of PI3P signaling in
transport from early to late endosomes in more detail. To
this end, we used a well-established assay that reconstitutes
the formation of the transport intermediates (multivesicular
bodies or endosomal carrier vesicles [ECVs]) from donor
early endosomes (Aniento et al., 1996). In this assay, the
content of early endosomes is labeled with the solute HRP,
and early endosomes are prepared. After in vitro incubation,
newly formed ECVs exhibit a lower density than donor early
endosomal membranes and are conveniently separated by
floatation in gradients. The efficiency of vesicle formation is
then calculated from the amounts of HRP present in donor
endosomes and vesicles formed in vitro. We confirmed with
an established fusion assay that ECVs formed in vitro were
Figure 3. PI3P signaling regulates 
EGFR sorting in early endosomes. 
(A) Cells expressing EGFR-GFP (pretreated 
with EGF, as in Fig. 1 A) were incubated 
for 10 min at 37 C with rhodamine-
dextran, followed by a 90-min chase 
with 100 nM wortmannin, labeled with 
antibodies against the indicated antigens 
and analyzed by triple channel fluor-
escence. (B) Cells transfected with GFP-
2xFYVE were incubated with EGF-biotin 
and streptavidin-phycoerythrin for 1 h 
at 4 C and then for 10 min at 37 C 
followed (chase) or not (pulse) by a 90-
min chase in the presence of leupeptin, 
labeled with antibodies against the indi-
cated antigens and analyzed by triple 
channel fluorescence. (C) Cells expressing 
GFP-2xFYVE (FYVE), or treated (wort) or 
not treated (control: ctrl) with wortmannin 
were labeled with endocytosed EGF-
biotin/streptavidin-phycoerythrin (as in 
B) or dextran (as in A), except that the 
chase time period was 45 min, and then 
processed for immunofluorescence using 
antibodies against the early endosomal 
(EE) marker EEA1 or the late endosomal 
(LE) marker LBPA, as indicated. For each 
condition, the total number of vesicles 
labeled with EGF or dextran was counted 
from  15 cells in three different experi-
ments (expressed as 100%), as well as 
the percentage of these vesicles that also 
contained the EE (EEA1 in control cells; 
FYVE in FYVE-expressing cells) or the LE 
endosomal marker LBPA (except with 
wortmannin, since the drug releases 
EEA1). (D) After EGF pretreatment (as in 
Fig. 1 A), cells overexpressing EGFR-
GFP were incubated for 10 min at 37 C 
followed (chase) or not (pulse) by a 35-
min chase with wortmannin (wort) and 
processed for immunofluorescence. 
(E) The number of vesicles in D that 
contained both GFP-EGFR and TfR was 
counted, and is expressed as a percent-
age of the total number of GFP-EGFR–
positive vesicles (C). Bars: (A and B) 
2.5  m; (D) 5  m.T
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functional (Aniento et al., 1993a; Gruenberg et al., 1989),
since they lost the capacity to fuse with early endosomes
(Fig. 4 E, and outline in A) in contrast to donor membranes
(Fig. 4 B, and outline in A), but acquired the capacity to
fuse with late endosomes (Fig. 4 D, and outline in A).
Using this assay, we found that the in vitro biogenesis of
ECVs was not affected by wortmannin or by GST-2xFYVE
(Fig. 4 C). Nor was the fusion of ECVs with late endosomes
(Fig. 4 D). As a control, we confirmed that both wortman-
nin and GST-2xFYVE, but not the inactive C215S mutant,
inhibited the homotypic fusion of early endosomes (Gruen-
berg et al., 1989) (Fig. 4 B), as expected, since the Rab5 ef-
fector EEA1 was released from endosomes by GST-2xFYVE
(Fig. 4 F). These observations thus demonstrate that PI3P
signaling is not required for ECV biogenesis in vitro and
subsequent docking/fusion with late endosomes.
We then used the same assay, but with the EGFR as a
marker instead of HRP. EGF-induced endocytosis of the re-
ceptor was allowed to proceed for a few minutes to accumu-
late EGFR in early endosomes. These were then purified
(Fig. 5 A) and used as donor membranes. In a highly selec-
tive manner, EGFR was incorporated into newly formed
ECVs (Fig. 5 C), in contrast to TfR, which remained in do-
nor membranes (Fig. 5 B). Interestingly, incorporation of
EGFR into newly formed ECVs was significantly reduced
when GST-2xFYVE, but not the inactive C215S mutant,
was added to the assay (Fig. 5 C). GST-2xFYVE was re-
cruited by donor membranes (Fig. 5 D) and to a lesser ex-
tent by ECVs depleted in EGFR (Fig. 5 C), consistently
with the distribution of PI3P on early endosomes and ECVs
(Gillooly et al., 2000). Similarly, EGFR incorporation into
newly formed ECVs was also inhibited by wortmannin (Fig.
5 C). The selective inhibition of EGFR, but not HRP, in-
corporation into ECVs by GST-2xFYVE, but not by the
C215S mutant, could be reproduced in vitro using donor
membranes containing both endocytosed HRP and EGFR
(not shown).
In our in vitro assay, EGFR and HRP were incorporated
into newly formed ECVs with a similar efficiency (Fig.
S3, available online at http://www.jcb.org/cgi/content/full/
jcb.200303018/DC1). Similarly, in vivo values for EGFR
and dextran were also in the same range. Clearly, however,
sorting and transport in vitro occurred with a somewhat re-
duced efficiency (
 
 
 
30%), when compared with the in vivo
situation, as expected. More importantly, EGFR sorting was
inhibited to the same extent by wortmannin and 2xFYVE in
vivo as well as in vitro, whereas these treatments did not af-
fect solute transport. Altogether, these data demonstrate that
Figure 3 continued.T
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EGFR sorting into ECVs, but not solute transport, is inhib-
ited when interfering with PI3P signaling.
Wortmannin was previously reported to inhibit MVB
morphogenesis by interfering with the membrane invagina-
tion process, thereby causing a vacuolation of early and late
endosomes (Reaves et al., 1996; Fernandez-Borja et al.,
1999; Futter et al., 2001). Under our experimental condi-
tions, however, wortmannin did not affect the appearance of
endosomes (Fig. 3), nor the amounts and distribution of
Figure 4. PI3P signaling is not necessary for 
ECV biogenesis. (A) The different transport 
steps that were studied in vitro are shown with 
reference to the corresponding panels: homo-
typic early endosome (EE) fusion (B), ECV 
biogenesis (C), and ECV fusion with late endo-
somes (LE) (D). ECVs lose the capacity to fuse 
with EEs in vitro (E) and acquire the capacity to 
fuse with LEs (D). (B–F) The homotypic fusion 
of early endosomes (B), the formation of ECVs 
(C), and the fusion of ECVs formed in vitro with 
late (D) or early (E) endosomes were measured 
in vitro in the absence (control) or presence of 
100 nM wortmannin, 3  g/100  g endosomal 
protein GST-2xFYVE or C215S mutant, and 
ATP, as indicated. Note the relatively high 
efficiency of ECV fusion with late (D) but not 
early (E) endosomes, when compared with 
the efficiency of ECV formation (C). (F) Early 
endosomes were incubated with or without 
GST-2xFYVE and analyzed by Western blotting 
using antibodies against the indicated proteins.
 
Figure 5.
 
PI3P signaling regulates EGFR sorting.
 
 (A) EGF was pulsed 
for 10 min at 37
 
 
 
C in cells expressing EGFR-GFP (pretreated with 
EGF, as in Fig. 1 A). Early endosome (EE), late endosome (LE), and 
heavy membrane (HM) fractions (Aniento et al., 1993a) were then 
analyzed by Western blotting using anti-GFP antibodies. (B–D) The 
in vitro formation of ECVs was measured (as in Fig. 4 C) using donor 
early endosomes from cells expressing EGFR-GFP (as in A) in the 
presence or absence of ATP, wortmannin (Wort), GST-2xFYVE, or 
C215S mutant. Fractions containing donor early endosomes (EE) 
and vesicles formed in vitro were analyzed by Western blotting 
using antibodies against the indicated antigens. In B and D, 50 
and 10% of the donor membranes (EE), respectively, were analyzed. 
Scanning of the lanes showed that, within the 30-min incubation 
of the assay, 
 
 
 
10% of the EGFR present in untreated donor membranes 
was incorporated into newly formed ECVs. This value is somewhat 
lower than EGF transport to late endosomes in vivo (
 
 
 
60% after 45 
min; Fig. 3 C), in part because one round of vesicle formation only 
is reconstituted in vitro (Aniento et al., 1993a).T
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LBPA, a marker of late endosome invaginations (Kobayashi
et al., 1998) (Figs. S1 and S2, available online at http://
www.jcb.org/cgi/content/full/jcb.200303018/DC1).
Hrs is likely to mediate the PI3P-dependent sorting of
EGFR into ECVs. Indeed, Hrs contains a FYVE domain, is
wortmannin sensitive and is involved in EGF down-regula-
tion, presumably by linking ubiquitinated EGFR with endo-
somal clathrin (Bishop et al., 2002; Lloyd et al., 2002; Rai-
borg et al., 2002). Hrs overexpression was previously found
either to inhibit (Bean et al., 2000) or not inhibit (Raiborg
et al., 2001) the recycling pathway, and to interfere with
EGFR and dextran transport from early to late endosomes
(Raiborg et al., 2001). After low Hrs-myc overexpression to
limit problems associated with high overexpression, EGFR
remained trapped in early endosomes containing Hrs-myc,
and failed to reach late endosomes (Fig. 6 B, and quantifica-
tion in A), in agreement with Raiborg et al. (2001). Dex-
tran, however, did not accumulate in Hrs-myc–labeled early
endosomes and reached late endosomes containing LBPA.
This apparent discrepancy with Raiborg et al. (2001), like
perhaps the differential effects of Hrs on the recycling path-
way (Bean et al., 2000; Raiborg et al., 2001), may well re-
flect differences in the levels of Hrs overexpression.
We therefore used our in vitro transport assay to further
investigate the role of Hrs in ECV biogenesis. Fig. 6 D
shows that cytosol depleted of Hrs by immunoprecipita-
tion failed to support EGFR incorporation into newly
formed ECVs (Fig. 6 E, and quantification in C). Cytosol
depleted of Rab7 (not shown), used as a control, was with-
out effect (Fig. 6, C and E). In contrast, the in vitro bio-
genesis of ECVs labeled with HRP was only marginally af-
fected by Hrs immunodepletion (Fig. 6 C). This agrees
with the findings that, despite defective membrane invagi-
nation, solute transport occurs along the degradation path-
way of hrs mutant 
 
Drosophila
 
 cells at a rate similar to wild-
type cells (Lloyd et al., 2002). Altogether, our in vivo and
in vitro data indicate that Hrs, like PI3P signaling, regu-
lates EGFR, but not solute, trafficking along the degrada-
tion pathway, strongly suggesting that Hrs mediates PI3P-
dependent EGFR sorting into ECVs.
Figure 6. Hrs regulates EGFR sorting, 
but not bulk transport to late endosomes. 
(A and B) As in Fig. 3 A and B, control 
cells (ctrl) or cells expressing either GFP-
2xFYVE (FYVE) or myc-Hrs were labeled 
with EGF-biotin/streptavidin-phyco-
erythrin or dextran, except that the marker 
was endocytosed for 45 min followed by 
a 60-min chase, and analyzed by triple 
channel fluorescence microscopy (B). 
In A, the colocalization of dextran or 
EGF with the early endosomal marker 
(EE, GFP-2xFYVE or myc-Hrs) or the 
late endosomal marker (LE, LBPA) was 
quantified as in Fig. 3 C. (C) ECV forma-
tion in vitro was measured with HRP 
as a marker, as in Fig. 4, using cytosol 
depleted of Hrs by immunoprecipitation 
(Hrs IP), or mock-treated with a control 
anti-Rab7 antibody (ctrl IP). (D) These 
cytosols (after Hrs immunoprecipitation 
or control immunoprecipitation, as in C) 
were analyzed by SDS electrophoresis 
and Western blotting with anti-Hrs 
( Hrs) antibodies. (E) The incorporation 
of GFP-EGFR into ECVs was followed as 
in Fig. 5, using Hrs-depleted or mock-
treated (Rab7) cytosol (as in C). GFP-
EGFR was analyzed in donor membranes 
(EE; 50% of the donor membranes) and 
vesicles (whole fraction) formed in vitro 
(vesicles) by Western blotting with anti-
GFP antibodies. The lanes were scanned, 
and the quantification is shown in C, 
as a percentage of the total amounts of 
GFP-EGFR in the vesicle fraction of con-
trols. Bar, 2.5  m.T
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In conclusion, our data show that bulk transport
from early to late endosomes in vivo and biogenesis of func-
tional endosomal intermediates in vitro are not affected,
when interfering with the PI3P signaling pathway or with
Hrs functions. In marked contrast, EGFR then remains
trapped within early/recycling endosomes, and fails to be
transported to late endosomes in vivo or to be incorporated
into newly formed endosomes in vitro. Similarly, the ubiq-
uitination machinery, which regulates EGFR sorting, does
not play a role in solute transport along the degradation
pathway (van Kerkhof et al., 2001). Our data thus show
that membrane transport and receptor sorting can be un-
coupled in the endosomal pathway. They also demonstrate
that, although PI3P signaling does not regulate the core
machinery of endosome transport, it controls the sorting of
down-regulated receptor molecules in early endosomes,
presumably via Hrs.
 
Materials and methods
 
Reagents
 
Wortmannin, EGF, and mouse IgG were from Sigma-Aldrich; fugene and
leupeptin were from Roche Diagnostic; anti-TfR antibody was from Zymed
Laboratories; anti-EEA1 antibody was from BD Bioscience; EGF-biotin and
10-kD rhodamine-dextran were from Molecular Probes; and rhodamine-
labeled or AMCA-labeled anti–mouse IgGs were from Jackson ImmunoRe-
search Laboratories. pGEX-2xFYVE and pGEX-2xFYVE
 
C215S
 
 have been de-
scribed (Gillooly et al., 2000), as well as anti-LBPA antibodies (Kobayashi
et al., 1998), and anti-Hrs antibodies and Hrs-myc (Raiborg et al., 2001).
EGFR-GFP was from Alexander Sorkin (University of Colorado, Denver,
Colorado).
 
In vivo experiments
 
When indicated, BHK-21 (Gruenberg et al., 1989) and HeLa cells (Rojo et
al., 1997) were transfected with fugene 36 h before the experiment. To la-
bel early or late endosomes, cells were incubated for 10 min at 37
 
 
 
C with
3 mg/ml rhodamine-dextran (pulse) or further incubated without the
marker (chase) for the indicated time period, with or without 100 nM wort-
mannin (for long incubations, the drug was always added freshly after 30
min). Alternatively, cells were first incubated for 1 h at 4
 
 
 
C with EGF-biotin
and streptavidin-phycoerythrin. The marker was endocytosed with the
same pulse–chase protocole as mentioned here. For quantification, cells
expressing or not expressing GFP-2xFYVE were separately incubated with
EGF-biotin/streptavidin-phycoerythrin (as described here), or with rho-
damine-dextran for 10 min, followed by a 45- or 60-min chase, and pro-
cessed for immunofluorescence. When indicated, cells were incubated for
16 h at 37
 
 
 
C with 40 µg/ml mouse IgG with or without 50 µg/ml leupeptin.
An EGFR-GFP cell line was obtained after transfection of BHK cells using a
lentiviral vector (Trono, 2002) with a construct encoding the EGFR fused to
GFP (Carter and Sorkin, 1998) under the control of a tetracycline pro-
moter. The clonal population was obtained by limited dilution after a first
selection by FACS.
 
Transport assays
 
Early and late endosomes were separated by floatation in a step sucrose
gradient (Aniento et al., 1993a; Gorvel et al., 1991), and recovered at
d 
 
 
 
 1.1031g/cm
 
3
 
 (35%/25% sucrose interface) and d 
 
 
 
 1.0772g/cm
 
3
 
(25%/8.5% sucrose), respectively. Cytosol was prepared from rat liver
(Aniento et al., 1993b), aliquoted, frozen, and stored in liquid nitrogen.
When indicated, the cytosol was depleted of Hrs by immunoprecipitation,
or mock-treated with anti-Rab7 as a control (Aniento et al., 1993a). The
homotypic fusion activity of early endosomes was measured after mixing
in the assay two early endosome populations, which had been separately
labeled with endocytosed biotinylated HRP and avidin, respectively
(Aniento et al., 1993a; Gruenberg et al., 1989). The mixture was incubated
with ATP and cytosol for 45 min at 37
 
 
 
C with or without PI3 kinase inhibi-
tors or 3 
 
 
 
g recombinant protein/100 
 
 
 
g endosomal protein. The avidin–
biotinylated HRP (bHRP) complex formed upon fusion was immunopre-
cipitated with anti-avidin antibodies, and the enzymatic activity of bHRP
was quantified and expressed as a percentage of the maximal amount of
avidin–bHRP complex formed after detergent solubilization (efficiency).
We measured the formation of ECVs from donor early endosomal mem-
branes, using endocytosed HRP as a marker of the endosomal content, as
described (Aniento et al., 1996; Gu and Gruenberg, 2000). In the assay,
donor early endosomes were incubated for 30 min at 37
 
 
 
C with ATP and
cytosol, with or without drugs or recombinant proteins, as above. ECVs
formed in vitro were separated by floatation in a sucrose gradient, and the
HRP content of both ECVs and donor membranes was quantified. The effi-
ciency of the reaction was calculated as the percentage of total HRP
present in ECVs formed in vitro. To measure the fusion activity of ECVs
formed in vitro with late endosomes, ECVs were prepared using biotin-
ylated HRP instead of HRP (Aniento et al., 1996; 1993b). The fusion assay
was carried out as described above for early endosomes, except that avidin
was endocytosed for 5 min followed by a 40-min chase, and then late en-
dosomal fractions were used in the assay. To study transport of EGFR-GFP
in vitro, cells were pretreated with 20 
 
 
 
g/ml brefeldin A for 1 h at 37
 
 
 
C, to
deplete early endosomes from Golgi markers (Gu et al., 1997; Rojo et al.,
1997). Cells were incubated for 1 h at 4
 
 
 
C with 0.5 
 
 
 
g/ml of EGF and 20
 
 
 
g/ml brefeldin A, and then for 10 min at 37
 
 
 
C, and fractionated as above.
In vitro formation of ECVs was as described here, except that cytosol and
donor membranes were reduced 10-fold and the volume of the reaction
was adjusted. Donor membranes and ECVs formed in vitro were analyzed
by SDS gel electrophoresis and Western blotting.
 
Other methods
 
The 2x FYVE motif was isolated from the pGEMEGFP 2xFYVE (Gillooly et
al., 2000) after an EcoRI-SalI digestion and introduced into the peGFPC2.
Recombinant GST-2xFYVE and C215S mutant were produced in bacteria
and purified (Cavalli et al., 2001). ELISA of LBPA in fractions was as de-
scribed using Immulon I 96-well plates (Kobayashi et al., 1998). Quantifi-
cation of protein was according to Bradford (1976). Western blot analysis
was carried out using peroxidase-conjugated sheep anti–mouse or goat
anti–rabbit IgG as secondary antibodies and detected by chemilumines-
cence using the ECL reagent (Amersham Biosciences). Immunofluores-
cence was as described (Rojo et al., 1997).
 
Online supplemental material
 
Figs. S1 and S2 illustrate our observations that LBPA is not affected by PI3-
kinase inhibition, and Fig. S3 includes detailed quantification of the
efficiency of transport measured in vivo and in vitro. All supple-
mental material is available at http://www.jcb.org/cgi/content/full/jcb.
200303018/DC1.
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